News

Among this series of 3D manganese-cobalt BTC metal organic frameworks is the perfect vessel to capture and raise the alarm on poisonous gas.

A blue-sky vision for a new, durable green polymer has won AIBN researchers global recognition at the 2024 Serendipity Collective competition in Estonia.

Professor Wang has been elected to a list of the nation's most distinguished scientists for his work in clean energy applications.

AIBN researchers Dr Helen Forgham and Dr Ruirui Qiao believe they have ideal vehicle to simultaneously treat, map and monitor the notoriously difficult Medulloblastoma tumour that occurs in children.

AIBN researchers scored four wins in the latest Investigator Grant round for nanotechnology projects that could change the way we approach certain diseases.

Ovarian cancer is notoriously difficult to pick up and claims the lives of 1000 women every year. AIBN researchers are hoping to change that with a new, portable blood test.

Work on a new range of hyper accurate cancer drugs has begun with the launch of an Australian-first research and manufacturing hub.

AIBN researchers are at the heart of a new era for medical research, one that will boost local biomanufacturing and help seriously unwell patients.

Professor Lianzhou Wang has been named UQ's first ever ARC Industry Laureate Fellow, winning $3.6 million to help position Australia as a leading supplier of superior batteries for electric vehicles.

Every groundbreaking innovation begins as an idea. At the AIBN our unique approach to biotechnology means we can streamline the journey from an idea to a commercial product.

AIBN Associate Professor Joy Wolfram believes decoding a cellular messaging system will give them the upper hand against a particularly deadly type of breast cancer.

Heart disease is a major killer in Australia – but researchers are a beat closer to remuscularising your dodgy ticker with a lab grown solution.

AIBN researcher Dr Nick Fletcher has won an Advance Queensland Industry Research Fellowship to explore localised cell death and the immune response to cancer.

What can the metabolism of 606 people from China, the Netherlands and Australia tell us about the onset and progression of ALS? Turns out, quite a bit.

For three months Tahmina Tabassum relearned what she knew about industry and entrepreneurship during a placement with biotech Azafaros BV, a whirlwind experience that included a stint at the company’s headquarters in Basel.

Early work has begun at the AIBN on a synthetic, drug-free solution that helps osteoarthritis patients with problem joints.

When it comes to precision medicine, advanced biomanufacturing and nanoengineered materials, if you dream it, the AIBN can do it.

Professor Kris Thurecht and the AIBN team are working to improve the targeting ability of these molecules to unlock the power of radiopharmaceuticals.

A University of Queensland (UQ) developed antiviral surface coating that protects against COVID-19 and other existing and emerging viral and bacterial transmissions is being tested on the International Space Station.

AIBN researchers want HIV patients to have the option of taking a long-acting antiretroviral dose once a week, instead of having to take a dose every day.